Impax Labs News Today

The “bogus” patent listings keep brand name drug prices “artificially high,” regulators said.

As discussed last month, the FTC sent letters to 10 pharmaceutical companies, asserting that their listing of over 100 patents in FDA’s Orange Book for a variety of products was...

I. Introduction - No pharmaceutical antitrust decision has had more impact than the Supreme Court’s 2013 decision in Federal Trade Commission v. Actavis, a decision which...

On Friday, August 25, 2023, the U.S. Court of Appeals For The District Of Columbia Circuit affirmed dismissal of an antitrust action brought by the Federal Trade Commission...

Reverse payment cases arise in the context of settlement agreements between brand-name pharmaceutical companies and generic drug manufacturers to resolve patent litigation under the Hatch-Waxman Act...

FDA has posted an Addendum to Briefing Document on its website that was circulated to members of the AdCom ... | May 9, 2023

The attorneys who secured a $145 million settlement for direct purchasers of Endo Pharmaceuticals's Opana ER who said they overpaid generic-drug maker Impax Labs for the prescription painkiller because of a pay-for-delay deal will walk away from the litigation with more than $50 million for their trouble.